Showing 1-10 of about 16 articles.
Autolus Therapeutics plc
LONDON, April 23, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the...
Equillium
LA JOLLA, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immune-inflammatory disorders, announced today that Bruce...
Equillium
LA JOLLA, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that the...
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company was granted orphan drug designation (ODD) by the U.S. Food and Drug Administration (FDA)...
Axsome Therapeutics, Inc.
NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Corbus Pharmaceuticals Holdings, Inc.
– Dermatomyositis is a rare chronic systemic autoimmune disease characterized by inflammation of muscles and skin – DM affects ~80,000 in the US, EU and Japan and has a 5-year mortality rate as...
Corbus Pharmaceuticals Holdings, Inc.
Phase 3 study follows positive 16-weeks Phase 2 data and further improvement in efficacy outcomes with open-label extension dosing at six months12-month 150 subject study with ACR/EULAR 2016 Total...
Corbus Pharmaceuticals Holdings, Inc.
– Dermatomyositis is a rare chronic systemic autoimmune disease characterized by inflammation of muscles and skin – DM affects ~80,000 in the US, EU and Japan and has a 5-year mortality rate as high...
Nohla Therapeutics
SEATTLE, July 16, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases,...
Emerald Health Pharmaceuticals Inc.
SAN DIEGO, Oct. 20, 2017 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), which is developing medications based on cannabinoid science, today announced that the U.S. Food and Drug...
Showing 1-10 of about 16 articles.
